Genoway licenses CRISPR/Cas9 tech from ERS Genomics

By The Science Advisory Board staff writers

June 7, 2021 -- French company Genoway has entered a nonexclusive license agreement with ERS Genomics that grants Genoway past and future access to ERS Genomics' CRISPR/Cas9 patent portfolio.

Genoway is focused on the development of genetically engineered preclinical research models, specifically modified mice, rat, and cell lines. The license will allow the company to broaden its rodent model offerings.

Financial details of the agreement were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.